Research programme: anti-phosphatidylserine monoclonal antibodies - Affitech/Avid Bioservices

Drug Profile

Research programme: anti-phosphatidylserine monoclonal antibodies - Affitech/Avid Bioservices

Alternative Names: 11.31; 1N11; 3J05; AT 004; AT 005; Fully human bavituximab; PGN 632; PGN 634; PGN 635

Latest Information Update: 28 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Affitech A/S; Peregrine Pharmaceuticals
  • Developer Affitech A/S; Avid Bioservices; Peregrine Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Phosphatidylserine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Age-related macular degeneration; Cancer; HIV infections; Lassa fever; Viral haemorrhagic fevers; Viral infections; Yersinia infections

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for research development in HIV-infections in USA (Parenteral)
  • 21 Apr 2018 Parmacodynamics data from preclinical trial in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 05 Jan 2018 Peregrine Pharmaceuticals is now called Avid Bioservices
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top